Soleno Therapeutics, Inc. (SLNO)

USD 68.29

(-5.36%)

Market Cap (In USD)

3.13 Billion

Revenue (In USD)

-

Net Income (In USD)

-38.98 Million

Avg. Volume

969.61 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
35.7-60.92
PE
-15.59
EPS
-4.38
Beta Value
-1.439
ISIN
US8342033094
CUSIP
834203200
CIK
1484565
Shares
45857300.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Anish Bhatnagar M.D.
Employee Count
-
Website
https://soleno.life
Ipo Date
2014-11-13
Details
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.